An Extended Feasibility Phase I/II Study of Methylenetetrahydrofolate (Arfolitixorin) and Pemetrexed Single Agent, Given as Neoadjuvant Treatment in Patients With Resectable Rectal Cancer

Rectal Cancer Clinical Trial

Official title:

An Extended Feasibility Phase I/II Study of Methylenetetrahydrofolate and Pemetrexed Single Agent, Given as Neoadjuvant Treatment in Patients With Resectable Rectal Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01397305
• Other study ID #: ISO-MC-091
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: April 14, 2011
• Est. completion date: October 16, 2014

Study information

• Verified date: September 2020
• Source: Isofol Medical AB
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine whether an optimal dose of [6R] 5,10-methylenetetrahydrofolate (arfolitixorin) in combination with pemetrexed are effective in pre-operative treatment of patients with resectable rectal cancer.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 24
• Est. completion date: October 16, 2014
• Est. primary completion date: October 16, 2014
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Pathological/ cytological diagnosis of adenocarcinoma of the rectum. Patients must have operable rectal cancer that is amenable to surgery.

• No prior therapy for rectal cancer

• Eastern Cooperative Oncology Group (ECOG) Performance status 0 or 1

• Adequate organ function

• Patient compliance and geographic proximity that allow adequate follow-up

• For women: Must be surgically sterile, postmenopausal, or compliant with a medically approved contraceptive regimen during and for 3 months after treatment; must have a negative serum or urine pregnancy test and must not be lactating.

• For men: Must be surgically sterile or compliant with a contraceptive regimen during and for 3 months after treatment.

• Estimated life expectancy of at least 12 weeks

• Signed informed consent

• At least 18 years of age

Exclusion Criteria:

• Concurrent administration of any other anti-tumor therapy.

• Treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry.

• Serious concomitant systemic disorders (e.g., active infection including HIV, cardiac disease) that in the opinion of the investigator would compromise the patient's ability to complete the study.

• Have previously completed or withdrawn from this study or any other study investigating pemetrexed.

• Are pregnant or breast-feeding.

• Second primary malignancy that is clinically detectable at the time of consideration for study enrollment.

• History of significant neurological or mental disorder, including seizures or dementia.

• Inability to interrupt aspirin or other nonsteroidal anto-inflammatory drugs (NSAIDs)

• Presence of clinically relevant third-space fluid collection that cannot be controlled by drainage or other procedures prior to study entry.

• Inability or unwillingness to be given 5,10-methylenetetrahydrofolate, vitamin B12 or dexamethasone.

Related Conditions & MeSH terms

• Rectal Cancer
• Rectal Neoplasms

Intervention

Drug:
• [6R] 5,10-methylenetetrahydrofolate (arfolitixorin)
10, 50, 100, 200, and 500 mg/m2 IV on day 1, day 8 day and day 15 of each 21-day cycle. 3 cycles.
• Pemetrexed
500 mg/m2 IV on day 1 of each 21-day cycle. 3 cycles.

Locations

Country	Name	City	State
Sweden	Sahlgrenska University Hospital	Göteborg

Sponsors (1)

Lead Sponsor	Collaborator
Isofol Medical AB

Country where clinical trial is conducted

Sweden, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Feasibility of Pemetrexed Prior to Surgery	Feasibility is defined as the ability to receive the total planned dose of pemetrexed (i.e., 1500 mg/m) administered over a period of no more than 9 weeks. Feasibility is measured as absence of the following toxicities: CTC grade 4 lasting >= 7 days, or febrile neutropenia; CTC grade 4 thrombocytopenia or grade 3 with bleeding.; CTC grade 3 nonhematologic toxicity (excluding nausea and vomiting, isolated CTC grade 3 ALT or AST that returns to the patient's pretreatment CTC grade within 3 weeks, or grade 3 fatigue lasting <7 days).	3 cycles (21-day cycles)
Secondary	Pathological Complete Response (pCR)		Surgery following 3 cycles (21-day cycles) of chemotherapy
Secondary	Number of Participants Receiving Sphincter Saving Surgery		Surgery following 3 cycles (21-day cycles) of chemotherapy
Secondary	Evaluation of qualitative and quantitative toxicities	Bleeding, anastomosis, leakage, serious infection.	Start of study treatment until last postoperative visit. Expected average 16 weeks.
Secondary	[6R] 5,10-methylenetetrahydrofolate tissue concentration determination		Surgery following 3 cycles (21-day cycles) of chemotherapy
Secondary	Correlation between 5,10-methylenetetrahydrofolate and HCy levels in blood	Blood samples are taken before start of study treatment, in conjunction with start of every study drug cycle, and after completed study treatment. HCy measurements performed using HPLC. 5-10-methylenetetrahydrofolate is measured in tissue biopsies (tumor and adjacent mucosa) sampled in conjunction with surgery. The tissue is collected before start of study treatment, during and after completed study treatment. 5,10-methylenetetrahydrofolate levels are measured using LC/MS/MS.	Samples taken prior before study treatment, during 3 cycles of chemotherapy and after completion of study treatment. Expected average 20 weeks.
Secondary	Correlation of folate gene polymorphisms and gene signature profiling with clinical outcome and toxicity profiles.	RT-PCR will be used to measure and determine the gene expression levels of the genes FPGS (Folylpolyglutamate synthase) and GGH (Gamma-glutamyl hydrolase). This translational research will be compared with the clinical outcome and toxicity profiles of patients.	Tissue to be collected from tumor and adjacent mucosa before start of study treatment, during and after completed study treatment. Expected average 20 weeks.
Secondary	Pharmacokinetic parameters of [6R] 5,10-mTHF, 5-formyl-THF, 5-methyl-THF and THF calculated from plasma	Plasma samples will be collected prior to study treatment, and at 10 minutes, 1, 2 and 4 hours after study treatment	Calculated on Day1 and Day15 after cycle 1 and 3